title: The challenge of defining standards of prevention in HIV prevention trials.
abstract: As new HIV prevention tools are developed, researchers face a number of ethical and logistic questions about how and when to include novel HIV prevention strategies and tools in the standard prevention package of ongoing and future HIV prevention trials. Current Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) guidance recommends that participants in prevention trials receive 'access to all state of the art HIV risk reduction methods', and that decisions about adding new tools to the prevention package be made in consultation with 'all relevant stakeholders'. The guidance, however, leaves open questions of both process and implementation. In March 2009, the Global Campaign for Microbicides, UNAIDS and the Centers for Disease Control and Prevention convened a consultation to develop practical answers to these questions. Fifty-nine diverse participants, including researchers, ethicists, advocates and policymakers, worked to develop consensus criteria on when to include new HIV prevention tools in future trials. Participants developed a set of questions to guide decision-making, including: whether the method has been recommended by international bodies or adopted at a national level; the size of the effect and weight of the evidence; relevance to the trial population; whether the tool has been approved or introduced in the trial country; whether adding the tool might lead to trial futility; outstanding safety issues and status of the trial. Further work is needed to develop, implement and evaluate approaches to facilitate meaningful stakeholder participation in this deliberative process.
authors.affiliation: The Bioethics Program, Union Graduate College, 80 Nott Terrace, Schenectady, NY 12308, USA. philpots@mail.uniongraduatecollege.edu
authors.forename: Sean
authors.initials: S
authors.lastname: Philpott
authors.forename: Lori
authors.initials: L
authors.lastname: Heise
authors.forename: Elizabeth
authors.initials: E
authors.lastname: McGrory
authors.forename: Lynn
authors.initials: L
authors.lastname: Paxton
authors.forename: Catherine
authors.initials: C
authors.lastname: Hankins
mesh_terms: D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D035843:Biomedical Research / Q000941:ethics / Q000379:methods / Q000592:standards; D002986:Clinical Trials as Topic / Q000941:ethics / Q000379:methods / Q000592:standards*; D015658:HIV Infections / Q000517:prevention & control*; D006805:Human Experimentation / Q000941:ethics / Q000592:standards; D006801:Humans; D007391:International Cooperation; D018570:Risk Assessment; D040242:Risk Reduction Behavior; D014480:United Nations; D014944:World Health Organization
chemical_list: D044966:Anti-Retroviral Agents